1.Oral azithromycin,oral and intravenous erythromycin treatment of respiratory tract mycoplasma infection curative effect and adverse reaction of contrast
Chinese Journal of Biochemical Pharmaceutics 2017;37(7):325-326,329
Objective To summarize analysis of respiratory tract mycoplasma infection in patients with oral azithromycin,oral and intravenous erythromycin treatment the clinical effect and safety.Methods From April 2014 to September 2016 received during the period of 120 patients with respiratory tract mycoplasma infection as the research object,were randomly divided into oral azithromycin, oral erythromycin group and intravenous erythromycin group,all patients were retrospectively analyzed the clinical therapeutic effects and adverse reactions occur.Results The total effective rate in treatment,oral azithromycin is higher than oral and intravenous treatment of erythromycin,Signs and symptoms in the incidence of adverse reactions and improve the time aspect,oral azithromycin is lower than the oral and intravenous treatment of erythromycin,diff there is statistical significance(P<0.05).Conclusion For respiratory tract mycoplasma infection adopt oral azithromycin compared with oral and intravenous erythromycin treatment,the effect is better,shorter symptom improvement,higher security,worthy of clinical popularization and application.
2.Effect of atorvastatin combined with benazepril on proteinuria of patients with IgA nephropathy
Chinese Journal of Primary Medicine and Pharmacy 2018;25(10):1307-1310
Objective To investigate the efficacy and safety of atorvastatin combined with benazepril in the treatment of proteinuria in patients with IgA nephropathy ,so as to provide guidance for clinical medication .Methods Eighty patients with IgA nephropathy were selected ,and they were randomly divided into the observation group and control group according to random number table , with 40 patients in each group .The observation group was treated with atorvastatin combined with benazepril ,and the control group was treated with benazepril .The treatment effect of the two groups was compared.Results Before treatment,the 24h urinary protein,mean arterial pressure,serum creat-inine,blood urea nitrogen,and blood potassium between the two groups had no statistically significant differences (t=0.125,1.273,0.321,0.207,0.719,all P>0.05).After treatment,the 24h urine protein and mean arterial blood pressure in the two groups were lower than those before treatment , and the differences were statistically significant (t=2.735,6.145,3.434,4.501,all P<0.05),which in the observation group were lower than those in the control group,the differences were statistically significant (t=3.121,2.170,all P<0.05).The changes of serum creatinine, blood urea nitrogen and serum potassium in the two groups had no statistically significant differences (all P>0.05) .Conclusion Atorvastatin combined with benazepril in the treatment of IgA nephropathy can significantly decrease urinary protein level,without the adverse reactions of increased urea nitrogen ,creatinine and hyperkalemia ,which is worthy of popularization and application .
3.The nucleoprotein of severe fever with thrombocytopenia syndrome virus processes a stable hexameric ring to facilitate RNA encapsidation.
Honggang ZHOU ; Yuna SUN ; Ying WANG ; Min LIU ; Chao LIU ; Wenming WANG ; Xiang LIU ; Le LI ; Fei DENG ; Hualin WANG ; Yu GUO ; Zhiyong LOU
Protein & Cell 2013;4(6):445-455
Severe fever with thrombocytopenia syndrome virus (SFTSV), a member of the Phlebovirus genus from the Bunyaviridae family endemic to China, is the causative agent of life-threatening severe fever with thrombocytopenia syndrome (SFTS), which features high fever and hemorrhage. Similar to other negative-sense RNA viruses, SFTSV encodes a nucleocapsid protein (NP) that is essential for viral replication. NP facilitates viral RNA encapsidation and is responsible for the formation of ribonucleoprotein complex. However, recent studies have indicated that NP from Phlebovirus members behaves in inhomogeneous oligomerization states. In the present study, we report the crystal structure of SFTSV NP at 2.8 Å resolution and demonstrate the mechanism by which it processes a ringshaped hexameric form to accomplish RNA encapsidation. Key residues essential for oligomerization are identified through mutational analysis and identified to have a significant impact on RNA binding, which suggests that correct formation of highly ordered oligomers is a critical step in RNA encapsidation. The findings of this work provide new insights into the discovery of new antiviral reagents for Phlebovirus infection.
Binding Sites
;
Crystallography, X-Ray
;
Mutation
;
Nucleocapsid Proteins
;
chemistry
;
genetics
;
metabolism
;
Phlebovirus
;
metabolism
;
Protein Binding
;
Protein Multimerization
;
Protein Structure, Quaternary
;
RNA, Viral
;
metabolism
;
Recombinant Proteins
;
biosynthesis
;
chemistry
;
genetics